Your browser is no longer supported. Please, upgrade your browser.
Settings
RETA [NASD]
Reata Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-7.74 Insider Own0.10% Shs Outstand36.20M Perf Week-3.24%
Market Cap4.51B Forward P/E- EPS next Y-7.82 Insider Trans-68.99% Shs Float29.83M Perf Month-11.46%
Income-266.40M PEG- EPS next Q-2.08 Inst Own81.20% Short Float12.42% Perf Quarter23.58%
Sales8.60M P/S523.97 EPS this Y16.10% Inst Trans-0.39% Short Ratio8.11 Perf Half Y20.97%
Book/sh10.20 P/B12.29 EPS next Y8.40% ROA-36.30% Target Price- Perf Year-18.41%
Cash/sh21.62 P/C5.79 EPS next 5Y- ROE-88.40% 52W Range76.34 - 186.82 Perf YTD1.37%
Dividend- P/FCF- EPS past 5Y- ROI-48.10% 52W High-32.92% Beta1.57
Dividend %- Quick Ratio7.00 Sales past 5Y-29.10% Gross Margin- 52W Low64.15% ATR5.71
Employees261 Current Ratio7.00 Sales Q/Q-35.70% Oper. Margin- RSI (14)41.52 Volatility4.38% 4.32%
OptionableYes Debt/Eq0.20 EPS Q/Q12.90% Profit Margin- Rel Volume0.37 Prev Close128.06
ShortableYes LT Debt/Eq0.00 EarningsMay 06 BMO Payout- Avg Volume456.91K Price125.31
Recom1.30 SMA20-5.14% SMA50-7.10% SMA2002.64% Volume170,764 Change-2.15%
May-24-21Initiated Goldman Buy $236
Apr-26-21Initiated Barclays Overweight $155
Jul-10-20Resumed Stifel Buy $315 → $280
Jun-17-20Initiated BTIG Research Buy $237
Nov-13-19Downgrade National Securities Buy → Neutral
Sep-26-19Initiated National Securities Buy $130
Sep-25-18Reiterated Leerink Partners Outperform $116 → $139
Sep-13-17Initiated Leerink Partners Outperform $43
Jul-25-17Reiterated Citigroup Buy $39 → $87
Apr-13-17Initiated Ladenburg Thalmann Buy $55
Feb-23-17Initiated Stifel Buy $38
Jan-25-17Initiated Robert W. Baird Outperform $43
Jun-20-16Initiated Piper Jaffray Overweight $33
Jun-20-16Initiated Citigroup Buy
Jul-19-21 06:19PM  
Jun-28-21 09:38AM  
Jun-07-21 01:30PM  
Jun-03-21 04:58AM  
May-20-21 10:14AM  
09:43AM  
May-19-21 03:34PM  
06:55AM  
06:45AM  
May-07-21 09:12AM  
May-06-21 08:30PM  
08:05AM  
07:20AM  
06:45AM  
06:30AM  
May-03-21 06:45AM  
Apr-29-21 05:06PM  
Apr-28-21 05:00PM  
08:47AM  
Apr-26-21 04:54PM  
10:22AM  
Apr-15-21 06:45AM  
Mar-30-21 01:23PM  
Mar-29-21 05:34PM  
Mar-23-21 01:53PM  
Mar-22-21 09:27AM  
Mar-02-21 09:47AM  
Mar-01-21 07:31PM  
12:54PM  
06:35AM  
06:30AM  
06:30AM  
Feb-22-21 06:45AM  
Feb-10-21 12:31PM  
Feb-04-21 04:55AM  
Feb-03-21 05:05AM  
Dec-21-20 07:55AM  
Dec-14-20 11:55AM  
10:36AM  
10:08AM  
08:00AM  
Dec-13-20 05:10PM  
Dec-12-20 05:51PM  
02:00PM  
Dec-11-20 09:10PM  
09:00PM  
02:00PM  
12:32PM  
11:00AM  
10:25AM  
Dec-10-20 04:06PM  
10:24AM  
Dec-09-20 05:57PM  
04:28PM  
01:30PM  
11:35AM  
11:00AM  
10:12AM  
Dec-08-20 07:00PM  
11:57AM  
10:11AM  
12:20AM  
Dec-07-20 06:20PM  
12:45PM  
11:00AM  
10:10AM  
Dec-04-20 06:00PM  
12:54PM  
Dec-03-20 01:05PM  
01:00PM  
11:53AM  
Dec-02-20 05:00PM  
02:45PM  
Dec-01-20 11:01PM  
09:48PM  
04:03PM  
11:17AM  
11:00AM  
Nov-29-20 11:00AM  
Nov-28-20 11:00PM  
11:19AM  
Nov-27-20 05:00PM  
01:30AM  
Nov-26-20 08:00PM  
11:21AM  
Nov-25-20 10:28PM  
02:40PM  
09:27AM  
07:35AM  
Nov-24-20 08:02PM  
05:00PM  
05:00PM  
04:45PM  
01:00PM  
12:00PM  
Nov-23-20 11:00PM  
02:34PM  
Nov-22-20 01:00AM  
Nov-21-20 02:30PM  
Nov-20-20 12:16PM  
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Meyer Colin JohnChief Research OfficerJun 15Sale141.8540,0005,673,88117,000Jun 16 04:04 PM
Meyer Colin JohnChief Research OfficerJun 14Sale144.0520,0002,881,02457,000Jun 16 04:04 PM
Castellanos ElaineVP, Chief Accounting OfficerJun 09Sale141.908,4541,199,63014,546Jun 09 04:28 PM
Castellanos ElaineVP, Chief Accounting OfficerJun 07Sale146.751,546226,88314,546Jun 09 04:28 PM
Castellanos ElaineVP, Chief Accounting OfficerMay 26Sale124.5510,0001,245,47014,546May 27 06:15 PM
Meyer Colin JohnChief Research OfficerNov 17Sale165.376,3951,057,57172,000Nov 18 04:19 PM
Meyer Colin JohnChief Research OfficerNov 16Sale171.0118,6053,181,57772,000Nov 18 04:19 PM
McClellan William D. Jr.DirectorNov 12Sale172.924,000691,6690Nov 13 03:53 PM
Castellanos ElaineVP, Chief Accounting OfficerNov 12Sale176.023,500616,07015,146Nov 13 03:44 PM
WORTLEY MICHAEL DChief Legal OfficerNov 11Sale179.3751,4299,224,6690Nov 12 05:03 PM
Huff James WarrenChief Executive OfficerNov 10Sale175.0064,97011,369,7560Nov 10 05:43 PM
Meyer Colin JohnChief Research OfficerNov 09Sale175.0025,0004,375,00072,000Nov 10 05:59 PM
McClellan William D. Jr.DirectorNov 09Sale150.014,000600,0400Nov 10 05:54 PM
Huff James WarrenChief Executive OfficerNov 09Sale175.0616,6872,921,29164,970Nov 10 05:43 PM
Bir Dawn CarterChief Commercial OfficerNov 09Sale162.5060,0009,750,3000Nov 10 05:30 PM
Soni Manmeet SinghCOO and CFOAug 14Buy100.213,000300,6303,000Aug 14 03:45 PM